logo
welcome
CNBC

CNBC

Merck says experimental RSV treatment protected infants in trial, paving way for potential approval

CNBC
Summary
Nutrition label

88% Informative

Merck said its experimental treatment showed positive results in a mid- to late-stage trial.

The pharmaceutical giant could emerge as a new competitor in the market for treatments against RSV .

Complications from the virus are the leading cause of hospitalization among newborns.

Merck presented the results at the medical conference IDWeek in Los Angeles .

VR Score

92

Informative language

96

Neutral language

31

Article tone

formal

Language

English

Language complexity

64

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

Affiliate links

no affiliate links